Diabetic Macular Edema

Diabetic retinopathy can cause swelling of the center of the retina, the macula, and vision loss.

What is a Diabetic Macular Edema

Diabetic macular edema is swelling in the retina associated with diabetes. This swelling can blur and distort the vision. The swelling occurs because the walls of the small blood vessels are progressively more damaged in diabetes, and there is leakage of blood and fluid into the cells of the retina. There are a variety of options to treat diabetic macular edema. The oldest treatment is laser for retinal swelling. It has been studied for decades and has been shown to be safe and effective. As with all treatments, it is not curative, and it is not without risk, but laser is one of the safest things that we do in diabetic retinal care. Other newer treatments for diabetic retinal swelling have been shown to improve vision even more than laser in some cases, and have also been shown to be safe and effective in large modern trials. These treatments are a variety of injections given into the eye in the office, and they are sometimes given alone and sometimes given with laser in addition. There are two major classes of injections used in diabetic macular edema, and those are small molecule injections and corticosteroid injections. The injections work in different ways to reduce the leakage and swelling in the retina, and sometimes the different types of injections are both used. The injections are administered under local anesthesia, and are often relatively well-tolerated by patients. Injections are also amongst the safest procedures performed in the retinal clinic, and the specific risks and benefits of injections will be discussed by your doctor. Most patients with blurred vision from diabetic macular edema enjoy an improvement in vision with treatment. Often, treatment to maintain vision is ongoing, and the long-term treatment plan is individualized to each specific patient in our practice.

What is a Laser?

When diabetic macular edema is caused by focal areas of leakage, laser treatment can be helpful. Studies were done in the 1980's validating the use of laser to reduce the risk of vision loss and improve vision in patients with diabetic macular edema. The advantage of laser of intravitreal injections is that laser treatment usually only needs to be repeated a few times. Intravireal injections are given monthly. The disadvantage of laser, is that it does not improve vision as much as intravitreal injections do when the center of the macula is swollen. Many physicians will use both laser and intravitreal injections depending on the area of the macula that is swollen and the findings on examination and testing.

Lucentis for Diabetic Macular Edema

Monthly Lucentis therapy is helpful for patients with diabetic macular edema. With laser only, about 15 percent of patients have substantial visual improvement at 2 years. With Lucentis therapy, about 40 percent of patients have a substantial improvement in visual acuity. Subsequent studies have shown that ongoing monthly treatment is usually not necessary to maintain the visual benefit.


Diabetic Macular Edema NEWS

Below are current articles from a Google News Feed on Diabetic Macular Edema

Subfoveal choroidal thickness in diabetic macular edema | OPTH  Dove Medical Press

Dalia Mohamed Fawzy Mohamed,1 Nihal Adel Hassan,2 Amr Abdellatif Osman,2 Moataz Hamed Osman2 1Department of Ophthalmology, National Institute of ...

AJMC® in the Press, June 14, 2019  AJMC.com Managed Markets Network

Coverage of our peer-reviewed research and news reporting in the healthcare and mainstream press.

Lutronic Vision's R:GEN™ Treats First CSC Patient at Seoul National University Hospital  GlobeNewswire

Korea's first retina treatment laser is available to treat Central Serous Chorioretinopathy -

New Treatment Approved for Diabetic Condition Leading to Blindness  Healthline

The drug Eyela can be used to treat the early stages of diabetic retinopathy, reducing the chances of serious vision loss.

Alimera Sciences Announces Launch of Direct-to-Patient Marketing Campaign to Raise Awareness and Educate Consumers on Diabetic Macular Edema and ILUVIEN®  GlobeNewswire

Pilot program to be initiated in four U.S. cities leveraging radio, print and social media channels, with potential for future expansion. ILUVIEN's CONTINUOUS ...

Cole Eye Institute Retina Summit 2019 Highlights  Healio

Education Lab | Cole Eye Institute Retina Summit 2019 Highlights.

When Anti-VEGF Agents Don't Work: Using Intravitreal Steroids Alone or in Combination to Treat DME/DR—Vision Is More Than Just Best Corrected Visual Acuity in Diabetic Macular Edema  Healio

Faculty Arshad M. Khanani, MD, MA (Chair) Clinical Associate Professor University of Nevada, Reno School of Medicine Managing Partner, Director of Clinical ...

Fluocinolone acetonide 0.19 mg intravitreal implant improves foveal th | IMCRJ  Dove Medical Press

Fluocinolone acetonide 0.19 mg intravitreal implant improves foveal thickness and reduces treatment burden for up to 1 year in eyes with persistent diabetic ...

Global Diabetic Macular Edema Drug Market Future Demand Analysis 2019  Industrial Reports

Global Diabetic Macular Edema Drug Market Professional Survey, Growth Factors, Shares, Opportunities and Forecast to 2025.

Oxurion releases phase 1/2 data of clinical study evaluating TR-317 for DME  Healio

THR-317 for the treatment of diabetic macular edema met its primary safety endpoint in a phase 1/2 study and also demonstrated efficacy, according to a press ...

Oxurion NV - Data from a Phase 1/2 Clinical Study evaluating THR-317 (anti-PlGF) for DME presented at 2019 FLORetina Meeting  GlobeNewswire

Leuven, Belgium, 6th June 2019 - 7 PM CET - Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company developing innovative treatments to ...

Regeneron Pharmaceuticals, Inc. - Consenus Indicates Potential 27.5% Upside  DirectorsTalk Interviews

Regeneron Pharmaceuticals, Inc. found using ticker (REGN) have now 21 analysts covering the stock with the consensus suggesting a rating of 'Buy'. The.

Diabetic Macular Edema Pipeline Report: Reviews Key Companies Involved and Enlists all their Major and Minor Projects  UK Blaze

Latest Pharmaceutical and Healthcare disease pipeline guide Diabetic Macular Edema - Pipeline Review, H1 2019, provides an overview of the Diabetic ...

Study shows OCTA detects changes in diabetic eyes sooner than OCT  Healio

VANCOUVER, British Columbia — OCT angiography was found to be more useful than OCT to detect changes in the eyes of patients with diabetes, according to ...

Watchful waiting reasonable for patients with diabetic macular edema and good vision  National Institutes of Health

People with good vision despite having center-involved diabetic macular edema can safely forego immediate treatment of their eye condition as long as they are ...

Worldwide Diabetic Macular Edema (DME) Market by Product, Distribution, End User & Forecast to 2024  The Scripps Voice

Diabetic Macular Edema (DME) Market report covers the disease overview, definition, classification, symptoms, ethology, pathophysiology and diagnostic ...

'Alarming' Complications in 20-Year-Olds With Type 2 Diabetes  Medscape

'I think we need to recognize that...in these younger kids we probably need even more aggressive management than many adults with type 2 diabetes,' says the ...

Aerie Pharmaceuticals Announces Appointment of Jeffrey Calabrese, CPA, as Director of Accounting  BioSpace

DURHAM, N.C.--(BUSINESS WIRE)-- Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, ...

Watchful Waiting OK in Diabetic Macular Edema With Good Vision  Medscape

Among patients with center-involved diabetic macular edema (CI-DME) who had good visual acuity, there were no significant differences in vision loss over a ...

Diabetic retinopathy: check the epidemic  Deccan Herald

Diabetic Retinopathy is one of the leading causes of vision loss in people with diabetes, especially the working age group.

Dr. Haqqani: Diabetic retinopathy diagnoses expected to increase  Midland Daily News

Diabetic retinopathy (DR) is recognized as the leading cause of vision impairment and blindness among those within working age (25 to 74). The Centers for ...

Global Diabetic Macular Edema Treatment Market | The Key Players-Regeneron Pharmaceuticals Inc., Pfizer Inc., Kubota Pharmaceutical Holdings Co. Ltd., Oculis, Bayer AG  The Market Research News

The data and information regarding the Global Diabetic Macular Edema Treatment Market industry are taken from trustworthy sources such as websites, annual ...

May 2019 Briefing – Diabetes & Endocrinology  Physician's Weekly

Jun 3, 2019 | HealthDay | 0 |. May 2019 Briefing – Diabetes & Endocrinology. Here are what the editors at HealthDay consider to be the most important ...

EyePoint Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)  Yahoo Finance

EyePoint Pharmaceuticals, Inc. (EYPT), a specialty biopharmaceutical company committed to developing and commercializing innovative ophthalmic products, ...

A better strategy for treating diabetic macular edema in people with good vision  EurekAlert

BOSTON - (April 29, 2019) - A change to the approach for treating diabetic macular edema may be on the way, thanks to a study published today in the Journal ...

Verseon Showcases Candidates for Next-Generation Diabetic Eye Disease Drugs  Business Wire

Verseon presented their oral drug candidates for diabetic macular edema (DME) at this week's 2019 BIO International Convention in Philadelphia. These.

Why Is Aerie (AERI) Down 10.2% Since Last Earnings Report?  Yahoo Finance

It has been about a month since the last earnings report for Aerie Pharmaceuticals (AERI). Shares have lost about 10.2% in that time frame, underperforming the ...

Aerie Pharmaceuticals to Present at Two Upcoming Investor Conferences  Yahoo Finance

Aerie Pharmaceuticals, Inc. , an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for ...

Optical coherence tomography patterns of diabetic macular edema in a S | OPTH  Dove Medical Press

Optical coherence tomography patterns of diabetic macular edema in a Saudi population Sanaa A Yassin,1 Saud M ALjohani,1 Arwa Z Alromaih,2 Abdulaziz A ...

Three-Year Clinical Trial Results Support ILUVIEN® Launch in Europe for the Prevention of Relapse in Recurrent Non-Infectious Uveitis Affecting the Posterior Segment  GlobeNewswire

A single ILUVIEN implant significantly delayed recurrence and reduced uveitis symptoms upon recurrence compared to active control arm. Recently approved in ...

Diabetic Macular Edema (DME) Epidemiology Clinical Area Segmentation 2019 to 2028  Market Trends

Latest Industry Research Report On “Diabetic Macular Edema (DME) – Epidemiology Forecast To 2028” in-depth analysis of the market state and also the ...

Roche Study Shows AI Can Detect Severity of Diabetic Macular Edema  BioSpace

The study showed that artificial intelligence can be used to provide widespread, cost-effective eye screenings via telemedicine to assist ophthalmologists in ...

Ophthalmic Sutures Market value to hit $443 Million by 2025: Global Market Insights, Inc.  GlobeNewswire

Asia Pacific ophthalmic sutures market is set to register over 6% CAGR from 2019 to 2025 supported by rising elderly population base that suffers from eye ...

Boost in Technology Driving the Retinal Biologics Market globally (2018-2028)  Wiki Times

Retinal biologics market value surpassed US$ 14.6 billion in 2018 and projected to grow at 10.7% y-o-y in 2019, as per a new FMI study. The projected growth ...

Cellectis S.A. (CLLS) and Clearside Biomedical Inc. (NASDAQ:CLSD) Comparison side by side  Stocks Beat

This is a contrast between Cellectis S.A. (NASDAQ:CLLS) and Clearside Biomedical Inc. (NASDAQ:CLSD) based on their institutional ownership, earnings and.

Diabetic Macular Edema Pipeline Insight 2019 – Research and Clinical Analysis  The Market Research News

Latest Industry Research Report On “Diabetic Macular Edema – Pipeline Insight, 2019” in-depth analysis of the market state and also the competitive landscape ...

Diabetic Macular Edema Treatment Market Analysis and Trends to 2025 | GlaxoSmithKline, Eyetech Pharmaceuticals, Alimera Sciences  Review Stocks Value

Los Angeles, June 03, 2019: Global Diabetic Macular Edema Treatment market report is first of its kind research report that covers the overview, summary, ...

Dexamethasone implant in the management of diabetic macular edema from | OPTH  Dove Medical Press

Mojca Urbančič,1 Ivana Gardašević Topčić2 1Eye Hospital, University Medical Centre Ljubljana, Ljubljana, Slovenia; 2Department of Ophthalmology, General ...

ONCURIOUS NV Receives Project Grant from VLAIO to Progress its Pipeline of Next Generation Cancer Immunotherapies  Yahoo Finance

Leuven, Belgium 11 June 2019 - ONCURIOUS NV, a Belgium-based biotech company focusing on the development of innovative oncology treatments, today ...

Macular Edema Market Growth and Sales Forecast 2017 – 2025  Amazing Newspaper

Macula is the oval yellowish area surrounding the focal point of the retina in the eye. Macular edema is the state when liquid and protein begin collecting under ...

EyePoint Pharmaceuticals Strengthens Executive Leadership Team with Key Hires  GlobeNewswire

Scott Jones Appointed as Chief Commercial Officer -. - Said Saim, Ph.D., Appointed as Chief Technology Officer -. WATERTOWN, Mass., June 10, 2019 (GLOBE ...

Allegro Ophthalmics Announces Positive Topline Vision Results of Phase 2 Study Evaluating Risuteganib in Patients with Intermediate Dry Age-Related Macular Degeneration  Yahoo Finance

Allegro Ophthalmics, LLC, a privately held biopharmaceutical company focused on the development of novel anti-integrin therapies for the treatment of ocular ...

Global Diabetic Macular Edema Drug Market Report: Regional Data Analysis by Production, Revenue, Price and Gross Margin  Industrial Journalism

Global Diabetic Macular Edema Drug Market offers a wide range of market dynamics like current trends (2019), estimated forecast (2025), segmentation by ...

Aerie Pharmaceuticals to Present at the Jefferies 2019 Healthcare Conference  Yahoo Finance

Aerie Pharmaceuticals, Inc. (AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class ...

Diabetic macular edema: the strategy for monitoring it in people who still have good vision  SciTech Europa

The research, published in the Journal of the American Medical Association. The study found that people with diabetic macular edema, who still have good ...

KalVista Pharmaceuticals Presents KVD900 Data at European Academy of Allergy and Clinical Immunology  Yahoo Finance

KalVista Pharmaceuticals, Inc. (KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small ...

Contrasting of Trevi Therapeutics Inc. (TRVI) and Clearside Biomedical Inc. (NASDAQ:CLSD)  Stocks Beat

This is therefore a comparing of the profitability, institutional ownership, analyst recommendations, risk, dividends, earnings and valuation in Trevi Therapeutics ...

Genprex Inc. (GNPX)'s Financial Results Comparing With Coherus BioSciences Inc. (NASDAQ:CHRS)  Stocks Beat

As Biotechnology businesses, Genprex Inc. (NASDAQ:GNPX) and Coherus BioSciences Inc. (NASDAQ:CHRS), are affected by contrast. This especially applies ...

Characteristics of diabetic macular edema on optical coherence tomogra | OPTH  Dove Medical Press

Characteristics of diabetic macular edema on optical coherence tomography may change over time or after treatment Shwu-Jiuan Sheu,1,2 Ying-Yen Lee,1 ...

KalVista Pharmaceuticals to Present Data at Upcoming Scientific Conferences  Yahoo Finance

Phase 1 Data on Oral Plasma Kallikrein Inhibitor KVD900 for Potential On-Demand Treatment of HAE Attacks to be Presented –

Reviewing Menlo Therapeutics Inc. (MNLO)'s and Clearside Biomedical Inc. (NASDAQ:CLSD)'s results  Stocks Beat

Menlo Therapeutics Inc. (NASDAQ:MNLO) and Clearside Biomedical Inc. (NASDAQ:CLSD), both competing one another are Biotechnology companies. We will ...

Difference in Treatment Effect Between Intravitreal Aflibercept Injection and Laser by Baseline Factors in Diabetic Macular Edema  Healio

Ophthalmic Surgery, Lasers and Imaging Retina | BACKGROUND AND OBJECTIVE:To evaluate the effect of baseline factors on differences in vision gains with ...

KalVista Pharmaceuticals Presents KVD900 Data at C1-Inhibitor Deficiency and Angioedema Workshop  Yahoo Finance

KalVista Pharmaceuticals, Inc. (KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small ...

Anti-VEGF Effective in Persistent Diabetic Macular Edema  Medscape

A recent analysis associated three different anti-VEGF agents with meaningful vision gains through 2 years of follow-up.

Comparison of Fortress Biotech Inc. (FBIO) and Regeneron Pharmaceuticals Inc. (NASDAQ:REGN)  Stocks Beat

Fortress Biotech Inc. (NASDAQ:FBIO) and Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) compete with each other in the Biotechnology sector. We will ...

Treatment patterns in diabetic macular edema in Taiwan: a retrospectiv | OPTH  Dove Medical Press

Treatment patterns in diabetic macular edema in Taiwan: a retrospective chart review Shwu-Jiuan Sheu,1,2 Cheng-Kuo Cheng,3,4 Hsi-Kung Kuo,5 Ching-Yao ...

Risuteganib complements anti-VEGF treatment for diabetic macular edema  Healio

VIENNA — Integrin inhibitor risuteganib was effective in complementing the anti-VEGF pathway when administered sequentially to an anti-VEGF drug in patients ...

Role of peripheral pan-retinal photocoagulation in diabetic macular ed | OPTH  Dove Medical Press

Ahmad M Mansour,1,2 Khalil El Jawhari,3 J Fernando Arevalo4 1Department of Ophthalmology, American University of Beirut, Beirut, Lebanon; 2Department of ...

LORATI Successfully Develops Effective Treatment for Diabetic Macular Edema Using Eye Drops  PRNewswire

TAIPEI, Taiwan, May 14, 2019 /PRNewswire/ -- Lorati Company Limited, a Taiwan-based biotechnology and pharmaceutical company, today announced that it ...

IRIDEX Announces Leadership Transition; David Bruce Appointed President and CEO  Yahoo Finance

We are pleased to appoint David Bruce to the role of President and CEO,” said Dr. Ruediger Naumann-Etienne, Lead Independent Director at IRIDEX. “David ...

Acucela Receives Orphan Designation From the EMA for Emixustat for the Treatment of Stargardt Disease  Global Banking And Finance Review

Acucela Inc. (Acucela), a clinical-stage ophthalmology company and wholly-owned subsidiary of Kubota Pharmaceutical Holdings Co., Ltd. (Tokyo 4596), ...

Global Diabetic Macular Edema Drug Market Shares, Trends, Outlook, Application, Future Scope & Market Statistics by 2025  Market Research Gazette

Diabetic Macular Edema (DME) is a leading cause of blindness among the working age population in most developed countries. DME is one of the major ...

Experimental drug delivers one-two punch to vision loss: Experiments show new therapy slows blood vessel leakage associated with diabetic macular edema and macular degeneration  Science Daily

In studies with lab-grown human cells and in mice, researchers have found that an experimental drug may be twice as good at fighting vision loss as previously ...

Alimera Sciences wins Health Canada nod for diabetic macular edema implant  Mass Device

Alimera Sciences (NSDQ:ALIM) said last month that it won approval in Canada for its intravitreal implant designed to treat diabetic macular edema. The Iluvien ...

Worldwide Diabetic Macular Edema Market Pipeline Insight Report (2018 – 2023)  The Downey Gazette

360 MARKET UPDATES Report provides a 360-degree overview of the global Diabetic Macular Edema Pipeline Insight Market with special emphasis on all ...

Alteogen Inc. gets IND approval for a clinical study in Korea for Eylea Biosimilar (ALT-L9) | Antibodies | News Channels  PipelineReview.com

Alteogen Inc. gets IND approval for a clinical study in Korea for Eylea Biosimilar (ALT-L9)

Diabetic Macular Edema Drugs Complete Product Development Cycle 2018  The Port Bulletin

“Diabetic Macular Edema – Pipeline Insight, 2018” report offers comprehensive insights of the pipeline (under development) therapeutics scenario and growth ...

Diabetic Macular Edema (DME) Market Forecast, Dimension, Methods, Developments, Key Producers and SWOT Evaluation 2024  Top 360 News

Diabetic Macular Edema (DME) Market report covers the illness overview, definition, classification, signs, ethology, pathophysiology and diagnostic strategies.

CPAP for OSA Does Not Improve Diabetic Macular Edema or Visual Acuity  Pulmonology Advisor

Continuous positive airway pressure (CPAP) therapy for obstructive sleep apnea (OSA) in patients with type 2 diabetes mellitus (T2DM) and diabetic macular ...

Diabetic Macular Edema Treatment Market to Grow CAGR of 1.45% to 2022  Burbank Observer

Diabetic Macular Edema Treatment market research is provided on major factors such as consumer needs and changes observed in them over time, market ...

Case Report on DME | Medpage Today  MedPage Today

An unexpected resolution of diabetic macular edema.

Deep Learning Models Could Boost DME Diagnosis Efficiency  MD Magazine

The best way to diagnose diabetic macular edema is using optical coherence tomography, but it is costly.

FDA OKs Aflibercept (Eylea) for Diabetic Retinopathy  Medscape

The US Food and Drug Administration (FDA) has approved aflibercept (Eylea, Regeneron) injection solution to treat all stages of diabetic retinopathy, the ...

BLOG: Laser still has an important role in diabetic eye disease  Healio

Ophthalmology Blogs | Mali | There is no question that the introduction of anti-VEGF agents has dramatically changed the landscape of how surgeons approach ...

Market Insights of Diabetic Macular Edema Therapeutics Market by Prime Main Gamers, Key Methods & Market Dynamics Forces  Top 360 News

The Diabetic Macular Edema Therapeutics Market report gives an unbiased and detailed evaluation of the on-going developments, alternatives/ excessive ...

The efficacy and safety of aflibercept and conbercept in diabetic macu | DDDT  Dove Medical Press

The efficacy and safety of aflibercept and conbercept in diabetic macular edema Siwei Cai, Qianhui Yang, Xiaorong Li, Yan Zhang Tianjin Medical University ...

Diabetic Macular Edema Market 2019 Global Leading Players, Industry Updates, Future Growth, Business Prospects, Forthcoming Developments and Future Investments by Forecast to 2026  K N Hearld

Diabetic Macular Edema Market 2019 research report would be to deliver the correct and tactical analysis of the market share, growth factors, demand, industry ...

Verseon Showcases Diabetic Eye Disease Oral Drug Candidates At BIO Worldwide Convention  TechBullion

Verseon introduced an alternative To Eye Injections For Diabetic Macular Edema Patients, solving one of the biggest problems of Diabetic patients. For decades ...

One in four anti-VEGF therapy patients with DME lost to follow-up  Healio

A quarter of patients with diabetic macular edema who received an anti-VEGF injection to treat nonproliferative diabetic retinopathy did not return for a follow-up ...

Global Non-infectious Macular Edema Treatment Market 2019: Growing Demand for Developing Economics, with Top Players and Forecast till 2024  Journallic

Non-infectious Macular Edema Treatment Market 2019 Research Report states that the Non-infectious Macular Edema Treatment industry is valued at XX ...

FDA Approves EYLEA® (aflibercept) Injection for Diabetic Retinopathy  BioSpace

FDA Approves EYLEA® (aflibercept) Injection for Diabetic Retinopathy - read this article along with other careers information, tips and advice on BioSpace.

Google launches India program to screen diabetics for eye conditions that can cause blindness  CNBC

Google and Verily teamed up to develop a screening tool for conditions that can cause preventable eye disease in adults. It is now being used at an eye hospital ...

No Benefit to Beginning Treatment Prior to Vision Loss in Most DME Cases  MD Magazine

A recent study found that early intervention before vision loss does little for patients compared to those who do not receive preemptive treatment.

Relationship Between Dry Retinal Volume and Visual Acuity in Diabetic Macular Edema  Healio

Ophthalmic Surgery, Lasers and Imaging Retina | BACKGROUND AND OBJECTIVE:To evaluate the relationship between a novel spectral-domain optical ...

EYLEA® (aflibercept) Injection Improves Diabetic Retinopathy and Reduces Vision-Threatening Complications in Phase 3 Trial  BioSpace

TARRYTOWN, N.Y., Oct. 25, 2018 /PRNewswire/ --. First trial in non-proliferative diabetic retinopathy to show both a reduction in vision-threatening ...

Jennifer Lim, MD: Training & Testing AI to Detect Diabetic Retinopathy  MD Magazine

After training the EyeArt system on thousands of images of eyes with diabetic retinopathy, investigators tested the AI in a clinical trial.

Study Explores Efficacy of Iluvien Implant Efficacy Over 3 Years  MD Magazine

Retrospective study assesses real-world outcomes of treating patients with chronic DME with Iluvien implant.

Belgian Biotech Completes First Trial with New Drug for Diabetic Macular...  Labiotech.eu

Belgian biotech ThromboGenics has conducted the first clinical trial of an antibody to treat one of the world's leading causes of vision loss.

Diabetes Awareness Month: I reversed my macular edema and lost 35lbs  Diabetes.co.uk

In this Diabetes Awareness Month success story we're featuring a man who went low carb and improved his health to the point where he reversed his macular ...

It’s smaller than a grain a rice and it’s helping reverse vision loss for diabetics  11Alive.com WXIA

ATLANTA — Think about a bag of rice. Focus on one tiny grain. Got the image? Good. Now, imagine something smaller than that singular piece of rice, being ...

Single Retinal Layer Changes After Subthreshold Micropulse Yellow Laser in Diabetic Macular Edema  Healio

Ophthalmic Surgery, Lasers and Imaging Retina | A pilot prospective, interventional study has been conducted on 10 patients with diabetic macular edema ...

Social cost of retinal blindness in US will be billions of dollars by 2020  Healio

FORT LAUDERDALE, Fla. — The direct, indirect, and intangible costs due to neovascular age-related macular degeneration, diabetic macular edema, and ...

Comparing of Geron Corporation (GERN) and Ampio Pharmaceuticals Inc. (NYSEAMERICAN:AMPE)  Stocks Beat

Geron Corporation (NASDAQ:GERN) and Ampio Pharmaceuticals Inc. (NYSEAMERICAN:AMPE) compete with each other in the Biotechnology sector. We will ...

Anti-VEGF Efficacy in DME: Early Response Is Not Destiny  Medscape

New data from Protocol T shows that eyes with poor 12-week response often had good vision at 2 years without switching therapies.

Global Diabetic Eye Disease Devices Market 2024: Advance Study by Business Summary, Gross Margin and Market Segment  TheSportMail

Global Diabetic Eye Disease Devices market 2019 research report on the Diabetic Eye Disease Devices market presents a brief scenario and the dynamics ...

Study Shows that Using AI in Eye Screenings Could Help Improve Vision Outcomes  Medical Device and Diagnostics Industry

A new study published in Investigative Ophthalmology & Visual Science suggests that artificial intelligence (AI) could be used to provide widespread, ...

Google and Verily reveal algorithm for diabetic eye disease screening  MedCity News

Google and Verily, Alphabet's life sciences and healthcare arm, have created a machine learning algorithm to help screen for diabetic retinopathy and diabetic ...

Charles Wykoff, MD, PhD: Context of the PANORAMA Trial  MD Magazine

PANORAMA is the first prospective study of high-risk patients with non-proliferative diabetic retinopathy, but not DME, in the anti-VEGF era.

Eylea's PANORAMA data give fuller view of efficacy in label expansion bid  BioPharma Dive

Significantly fewer patients with advanced forms of a diabetic eye disease experienced vision-threatening events when taking Regeneron Pharmaceuticals' ...

Most effective treatment approaches for uveitic macular edema  Science Daily

Injections of corticosteroids directly into the eye are superior to those placed adjacent to the eye for treating uveitic macular edema, one of the leading causes of ...

» Load more